Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

GAMBA · Gene Activated Matrices for Bone and Cartilage Regeneration in Arthritis

FP7Status: CLOSED1 September 201031 August 2013EU funding €3,198,849

This consortium develops a novel gene-activated matrix platform for bone and cartilage repair with a focus on osteoarthritis-related tissue damage. The S&T objectives of this project are complemented with an innovative program of public outreach, actively linking patients and society to the evolvement of this project. The GAMBA platform is going to implement a concept of spatiotemporal control of regenerative bioactivity on command and demand. A gene-activated matrix is a biomaterial with embedded gene vectors that will genetically modify cells embedded in the matrix. The platform comprises modules that self-adapt to the biological environment and that can be independently addressed with endogenous biological and exogenous physical or pharmacological stimuli, resulting in a temporally and spatially coordinated growth factor gene expression pattern. This reproduces, within the matrix, key elements of natural tissue formation. The modules are a biomimetic hyaluronan gel, a ceramic matrix, growth factor-encoding gene vector nanoparticles, magnetic nanoparticles and mesenchymal stem cells. Anatomical adaptivity is achieved with engineered thermal properties of the polymer matrix, which embeds other modules, selected according to functional requirements. Mechanical support is provided by Micro Macroporous Biphasic Calcium Phosphate (MBCP™), a resorbable material approved for clinical use. Spatiotemporal control of bioactivity and responsiveness to physiological conditions is represented, firstly, in the spatial distribution and release profiles of gene vectors within the composite matrix and, secondly, by letting local and external biological or physical stimuli activate the promoters driving the expression of vector-encoded transgenes. This innovative concept is implemented by a multidisciplinary team from leading European institutions combining scientific excellence with a focused plan of dissemination, public participation, gender equality and transition to market.

Consortium · 9 organisations

coordinator

KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN

DE · €619,792

participant

UNIVERSITY OF GALWAY

IE · €381,999

participant

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

FR · €190,500

participant

AO-FORSCHUNGSINSTITUT DAVOS

CH · €457,798

participant

BIOMATLANTE

FR · €349,560

participant

ScienceDialogue Dr. Karin Zöller, Maren Schüpphaus und Sven Siebert GbR

DE · €244,600

participant

OZ BIOSCIENCES SAS

FR · €330,800

participant

IRCCS OSPEDALE POLICLINICO SAN MARTINO

IT · €269,600

participant

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

NL · €354,200

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.